Hamm, Charlie A. http://orcid.org/0000-0003-4104-4758
Baumgärtner, Georg L. http://orcid.org/0000-0003-3046-0019
Padhani, Anwar R.
Froböse, Konrad P.
Dräger, Franziska
Beetz, Nick L.
Savic, Lynn J. http://orcid.org/0000-0003-2115-6728
Posch, Helena
Lenk, Julian
Schallenberg, Simon
Maxeiner, Andreas
Cash, Hannes
Günzel, Karsten
Hamm, Bernd
Asbach, Patrick
Penzkofer, Tobias
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 3 November 2023
Revised: 19 February 2024
Accepted: 22 February 2024
First Online: 28 March 2024
Change Date: 17 April 2024
Change Type: Update
Change Details: Sections "Development of a biopsy decision strategy using PI-RADS and sPSAD" and "Outcomes and statistics" have been formatted as sub-sections of section "Methods".
Declarations
:
: The scientific guarantor of this publication is Tobias Penzkofer.
: The authors of this manuscript declare relationships with the following companies, which however did not influence the presented study: A.R.P. Stockholder of Lucida, speakers beaureu for Siemens and research support of Siemens; L.J.S., P.A., B.H., and T.P. receive research grants from the Collaborative Research Center (CRC) 1340 “Matrix in Vision” funded by the Deutsche Forschungsgemeinschaft (DFG). L.J.S. Research grants, travel stipends, and lecture honoraria from Guerbet; B.H. Consulting fees from Canon/Toshiba; travel support from Canon and Bayer; stock options from pharmaceutical and medical technology companies. T.P. AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Dohme Corp, Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, MedImmune, Merck Sharp, Millennium Pharmaceuticals, Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Roche, Siemens Healthineers, and TESARO.Prof. Bernd Hamm is the Editor-in-Chief of <i>European Radiology</i>. As such, he had no role in handling this manuscript and finalizing decisions.
: Several authors have significant statistical expertise (G.L.B., A.P., T.P.).
: Informed consent was waived given its retrospective design.
: The Institutional Review Board of the Charité Universitätsmedizin Berlin approval was obtained.
: A subset of the study population investigated here was previously reported in Hamm et al Radiology 2023 (overlap of 75% (1210 men), development of an explainable deep learning system for prostate cancer detection), Beetz et al 2022 (29%, biopsy accuracy correlated with number of biopsy cores), Rudolph et al European Radiology 2020 (28%, validation of PI-RADS features), Beetz et al RöFo 2022 (20%, intra-reader comparison of PI-RADS version 2 and 2.1), and Rudolph 2020 (6%, intra-reader comparison of PI-RADS version 2 and 2.1). However, zone-specific PSAD and biopsy decision strategies using PSAD and PI-RADS were not investigated for prostate cancer detection.
: • retrospective• diagnostic or prognostic study• performed at one institution